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Abstract 
The importance of biopharmaceutical considerations in pharmaceutical development and drug 
characterization has been well recognized both by pharmaceutical industry and regulatory 
authorities as a tool to establish predictive relationships between drug product quality 
attributes (in vitro data) and its clinical performance (in vivo data). In the present paper, 
contemporary biopharmaceutics toolkit including in vivo predictive dissolution testing, 
Biopharmaceutics Classification System, physiologically based pharmacokinetic and 
biopharmaceutics modeling and simulation, in vitro-in vivo correlation and biowaiver, are 
reviewed with regards to relevant general principles and applicability. The recently introduced 
innovative strategy for patient-centric drug development using an integrated systems 
approach grounded in fundamental biopharmaceutics concepts, clinical insights and 
therapeutic drug delivery targets, described as Biopharmaceutics Risk Assessment Roadmap 
(BioRAM) is also presented. Further development in the field will benefit from joint efforts and 
exchange of knowledge and experiences between pharmaceutical industry and regulatory 
authorities for the common goal to accelerate development of effective and safe drug products 
designed in accordance with patients’ needs and expectations. 
Keywords: biowaiver; clinical performance; dissolution testing; in vitro-in vivo correlation; 
physiologically based pharmacokinetic/biopharmaceutics modeling.
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1. INTRODUCTION 
The importance of biopharmaceutical considerations in drug product development have been emphasized in the 
seminal work of Stanley Kaplan in the early 1970s [1,2]. It has been recognized that „the biological availability of a drug is 
the result of many processes. Factors such as low solubility, slow dissolution or release rate, poor permeability, gastrointes-
tinal degradation, and rapid biotransformation may all contribute to poor availability“, and that „in the development of the 
new drug, a sequentially designed biological availability study does not begin with a drug formulation, it results in a drug 
formulation“ [1]. Furthermore, drug solubility in the gastrointestinal lumen and permeability across the gastrointestinal 
wall were identified as „critical parameters associated with drug absorption“ following oral dosage form administration [2]. 
This was further elaborated and employed as the basis of the Biopharmaceutics Classification System introduced by 
Amidon et al in 1995 [3]. More recently, John Hodgson [4] provided a lively definition of a drug stating that “A chemical 
cannot be a drug, no matter how active nor how specific its action, unless it is also taken appropriately into the body 
(absorption), distributed to the right parts of the body, metabolized in a way that does not instantly remove its activity, and 
eliminated in a suitable manner – a drug must get in, move about, hang around, and then get out.” 
The importance of biopharmaceutical considerations in pharmaceutical development has been incorporated in the 
relevant Quality-by-Design (QbD) and Biopharmaceutics Risk Assessment Roadmap (BioRAM) concepts. These 
contemporary approaches which put the patient at the centre of the drug product development by exploring the specific 
patient needs, expectations and the desired therapeutic outcome, aim to link drug product physicochemical and 
biological properties (i.e. Critical Quality Attributes, CQA) with its clinical performance [5-9]. 
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In the present paper, different biopharmaceutical tools and principles governing application of the integrated 
biopharmaceutical approach in pharmaceutical development and drug characterization are reviewed. 
2. BIOPHARMACEUTICS TOOLKIT 
Modern biopharmaceutics toolkit, which is used in drug product development, characterization and regulatory 
approval includes relevant in vitro, in vivo and in silico approaches, which can be combined to explore, model, and 
predict the rate and extent of oral drug delivery. Although long sought after as a surrogate for in vivo studies (i.e. such 
as in biowaiver), in vitro dissolution testing is increasingly accepted as a reliable indicator of the drug product clinical 
performance when used complementary with physiologically based pharmacokinetic/biopharmaceutics modeling 
(PBPK/PBBM) and in vitro-in vivo correlation (IVIVC). 
2. 1. In vivo predictive dissolution testing 
In vitro dissolution testing is generally accepted as the most important test for dosage form characterization, which 
is used in different phases of the product life-cycle, starting from the early development stages, through product 
optimization, including stability assessment, technology transfer, routine quality control and post-approval changes 
justification. Within the integrated biopharmaceutical approach in pharmaceutical development and drug charac-
terization, dissolution testing is expected to serve as a substitute for in vivo testing, and the focus is placed on the 
discriminatory in vivo predictive dissolution test development and establishment of clinically relevant dissolution 
specifications [10-12]. While the most often used dissolution equipment for oral dosage form characterization includes 
compendial rotating paddle/rotating basket apparatus, extensive research efforts are directed towards design of 
dynamic apparatus which would more closely mimic hydrodynamics and transit times encountered in vivo, including 
the use of complex media, which simulate composition of physiological fluids in different parts of the gastrointestinal 
tract [13-16]. Two distinct approaches have been recognized: (i) biorelevant dissolution method which attempts to 
mimic complex factors, which are encountered under the physiological conditions in vivo, and may be useful in guiding 
formulation development and identification of food effects, and (ii) in vivo predictive (or, biopredictive) dissolution (iPD) 
method which includes a set of testing conditions that enable prediction of relevant pharmacokinetic profile, and is 
typically based on the established IVIVC [17]. The dissolution setup, which provides meaningful relationship between 
the data obtained in vitro and in vivo would enable evaluation of the impact of formulation factors and process 
parameters on the drug product clinical performance and identification of clinically relevant specifications. This implies 
that a clinically relevant dissolution method may be performed by using biorelevant dissolution conditions, but also that 
more simple experimental conditions may suffice as long as the method and acceptance criteria are capable of 
confirming or predicting in vivo drug performance [17-19].  
2. 2. Biopharmaceutics Classification System 
The Biopharmaceutics Classification System (BCS) has been introduced in 1995. as a theoretical framework to classify 
drug substances based on their gastrointestinal solubility and permeability as fundamental parameters controlling the rate 
and extent of drug absorption [3]. It has been widely accepted as an important biopharmaceutical tool in drug development 
and regulatory evaluation [20,21]. However, drug classification based on solubility and permeability is not straightforward 
and currently established low/high solubility and permeability boundaries are a subject of the ongoing scientific 
discussions. More recently, it also received considerable criticism for being overly conservative with respect to the 
established pH-solubility criteria, available media volume, applicability for the specific patient groups (such as paediatric 
population), veterinary applications, and applicability for other routes of drug administration (i.e. inhalation route, topical 
application), so that several modified classification systems have been proposed to address these limitations [22- 31].  
2. 3. Physiologically based pharmacokinetic and biopharmaceutics modeling and simulation 
A growing concern for biopharmaceutical characterization of drugs/pharmaceutical products prompted the develop-
ment of in silico models for the prediction and mechanistic interpretation of the drug in vivo performance. One may find 
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various terms describing these modeling tools such as physiologically based pharmacokinetic (PBPK) models, physio-
logically based biopharmaceutics models (PBBM) or model informed drug development (MIDD) tools, but they all refer to 
the same object - a wide range of quantitative models used in drug development to understand absorption, distribution, 
metabolism, excretion and toxicity (ADMET) of drugs, and consequently, to facilitate the decision-making process. 
PBPK models are basically mathematical models that integrate physiological parameters of humans (or animals) with 
drug and formulation properties to predict the expected pharmacokinetic outcome. They evolved rapidly, starting from a 
simple model of human gastrointestinal (GI) tract [32] to current complex models that integrate a number of parameters, 
able to simulate complex physiological mechanisms and drug disposition through different tissues [33-36]. Some of these 
models have been integrated in commercial software packages like GastroPlusTM (SimulationsPlus Inc, USA), Simcyp 
Simulator (Simcyp Limited, Certara, Inc. UK) and PK-Sim® (Bayer Technology Services GmbH, Germany). Furthermore, new 
knowledge about human physiology and disease-related changes enabled in silico estimation of drug performance in 
different patients and population groups [37-40]. PBPK models can conform different dosing routes, but major efforts have 
been directed to predict pharmacokinetics of orally administered drugs. A schematic representation of a PBPK model 
describing drug transport, absorption and disposition following oral administration is provided in Figure 1.  
 
 
Figure 1. Representation of a PBPK model that describes drug transport, absorption and disposition following oral drug 
administration 
 
PBPK models integrate a vast number of input parameters which need to be carefully selected and justified. Depending 
on available data, different modeling approaches can be used. Bottom-up approach is generally used for early predictions, 
based on drug physicochemical and some pharmacokinetic properties. But if clinical data are available, one can use the 
top-down approach and, for example, test hypotheses about the mechanisms governing drug absorption. The middle-out 
approach uses human in vivo data to confirm the model or make further refinements, such as parameter optimization.  
The examples of PBPK modeling applications are numerous, ranging from sensitivity analysis and mechanistic 
interpretation of drug absorption to food effect evaluation, biowaiver justification, IVIVC development and virtual trials, 
including virtual bioequivalence studies. One of the fundamental modeling utilities is the possibility to mechanistically 
interpret oral absorption patterns of drugs with different biopharmaceutical properties, and understand the influence of 
drug properties, formulation factors and patients’ physiological characteristics on the predicted pharmacokinetic profiles. 
Also, PBPK modeling can elucidate the combined mechanisms responsible for the positive or negative food effect on drug 
Hem. Ind. 74 (6) 389-397 (2020) S. V. CVIJIĆ et al.: PHARMACEUTICAL DEVELOPMENT AND DRUG CHARACTERIZATION 
792  
absorption. Other modeling features include prediction of pharmacokinetic outcomes for different drug doses, different 
dosage forms, different patients etc. Moreover, virtual population studies enable estimation of the expected variability in 
drug performance in the selected group of subjects. It should be also noted that these models offer a distinctive 
opportunity to test hypotheses and explore “what-if” scenarios in cases when clinical studies are not feasible.   
However, besides “pros”, there are certain “cons” related to PBPK modeling, such as the lack of information on drug 
biopharmaceutical properties and and/or lack of in vivo data for model verification in some cases. Furthermore, our 
knowledge of human physiology is still rather limited. And finally, PBPK/PBBM modeling tools are sophisticated and 
complex, so adequate level of proficiency is required for their appropriate use. 
2. 4. In vitro-in vivo correlation 
An in vitro - in vivo correlation (IVIVC) is a mathematical model describing the relationship between an in vitro 
property of a dosage form (mainly dissolution or drug release) and a relevant in vivo response (mainly drug plasma 
concentration or amount absorbed) [41]. Within the new pharmaceutical quality paradigm and QbD, IVIVC is seen as a 
bridge linking pharmaceutical quality of the product and its clinical relevance [42,43]. This type of relationship may be 
expected for products containing poorly soluble drugs, and when the formulation controls the rate of appearance of 
drug in plasma, such as in the case of modified/extended release dosage forms. Development of meaningful IVIVC is the 
ultimate goal of biopharmaceutics drug characterization, which facilitates the formulation development, discriminatory 
dissolution method development and provides support for a clinically relevant dissolution specification establishment 
and biowaiver justification in different phases of the product life-cycle.  
Although different levels of IVIVC have been described, including levels A, B, C and the multiple level C, the most 
useful and acceptable from both the industrial and regulatory points of view is the level A IVIVC. The level A IVIVC 
represents a point-to-point correlation between the predicted and in vivo observed plasma concentration - time profiles 
(e.g. convolution approach), or between the drug release profile observed in vitro and the relevant in vivo drug delivery 
input estimated by using different deconvolution approaches. In order to develop a meaningful IVIVC, at least three 
formulations with different drug release rates (i.e. slow, medium and fast) should be obtained and thoroughly 
characterized both in vivo and in vitro. In vivo study in the group of healthy volunteers should also include administration 
of the relevant reference dosage form with high bioavailability, such as intravenous bolus, oral solution or oral 
immediate release dosage form in order to obtain a unit impulse response (UIR) for deconvolution. Although 
conventional pharmacokinetic analysis based on the Wagner-Nelson method (in the case of one-compartment), and 
Loo-Riegelman method (in the case of a two-compartment pharmacokinetic model) can be employed to estimate the 
in vivo drug delivery input (i.e. hypothetical rate of drug absorption, or drug dissolution in vivo), the preferred and most 
frequently used is a two-stage approach based on numerical deconvolution [43]. Comprehensive in vitro charac-
terization of the investigated formulations should be performed, using different experimental conditions with regards 
to media composition and hydrodynamics/agitation employed. The relationship between the estimated in vivo and in 
vitro profiles is then evaluated by using the linear regression analysis, or the applicable non-linear model. In order to 
compensate the eventual disproportion between the in vivo and in vitro profiles, appropriate time shifting/scaling may 
be employed. The concept of IVIVC development is schematically presented in Figure 2. 
Introduction of PBPK/PBBM modeling, which integrates anatomical and physiological parameters of the 
gastrointestinal tract with the physicochemical properties of the drug substance and drug product properties enabled 
a model independent, mechanistic estimation of the in vivo drug delivery input based on the drug substance physico-
chemical and biopharmaceutical properties, thus overcoming certain limitations of the conventional deconvolution-
based approach [43]. The increased applicability of PBPK/PBBM in IVIVC development has been demonstrated in several 
published studies [44-49].   
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Figure 2. Schematic presentation of the IVIVC concept 
2. 5. Biowaiver 
Within the integrated biopharmaceutical approach in the pharmaceutical development and drug characterization, the 
term “biowaiver” is used to denote the regulatory drug approval process in which the dossier (application) is approved 
based on evidence of equivalence other than the in vivo bioequivalence test. The regulatory exemption from the in vivo 
bioequivalence studies must be based on the sound justification of the drug substance and drug product properties and 
the results obtained by comparative dissolution testing. At present, biowaiver is applicable for additional/lower strengths 
of proportionally similar formulations, immediate release solid dosage forms containing high solubility compounds (BCS 
class 1 and 3 drugs) and modified/extended release formulations with established IVIVC [21,50-52].  
3. OPTIMIZATION OF A DRUG PRODUCT CLINICAL PERFORMANCE 
Drug product in vivo performance is affected by a number of factors reflecting drug substance and dosage form 
properties, as well as the patient physiological status. Therefore, a thorough assessment of the potential factors that 
may influence the drug clinical performance is a priority in the pharmaceutical development. Formulation scientists use 
different tools to assess drug substance/drug product biopharmaceutical properties including in vivo clinical studies, 
biopredictive in vitro experiments, as well as computer-aided (in silico) modeling and simulations. Optimal clinical 
performance refers to accomplishment of the desired therapeutic response, drug safety, adequate product stability and 
minimization of inter-patient variability. 
The innovative strategy for the patient-centric drug development using an integrated systems approach grounded 
in fundamental biopharmaceutics concepts, clinical insights and therapeutic drug delivery targets is described as the 
Biopharmaceutics Risk Assessment Roadmap (BioRAM) [7-9]. The aim of the BioRAM and the BioRAM Scoring Grid is to 
facilitate optimization of drug products clinical performance. In the BioRAM, risk is defined as not achieving the intended 
in vivo drug product performance, and success is assessed by time to decision-making and action. The integrated 
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product development starts with exploration of specific patient needs and desired therapeutic outcome and employs 
all available resources to secure clinical understanding of the impact and utility of new molecules in pharmacotherapy. 
The key items and impact that have to be considered include: understanding of the molecular mechanistic target for 
the intended therapeutic outcome; development of the relevant drug delivery approach taking into account patient 
needs; assessment of drug substance physicochemical and biopharmaceutical properties; identification of PK or PD 
effects leading to characterization of the target input profile (i.e. in vitro and in vivo dissolution/release profiles), 
development of a suitable formulation approach and robust and reliable assessment tools [7]. 
4. INDUSTRIAL APPLICATION AND REGULATORY RECOGNITION 
Majority of available biopharmaceutics tools have been embraced within the pharmaceutical industry as an integral 
part of a drug development strategy aimed to support and accelerate regulatory approval of new drug products. 
Pharmaceutical companies act as a driving force for further development in the field. Recent advances related to the 
integrated biopharmaceutics approach in drug development and characterization resulted from the joint efforts of 
industry and academia working together on the major global projects and initiatives (such as the IMI funded OrBiTo 
project, UNGAP Cost action, International Consortium for Innovation and Quality in Pharmaceutical Development). With 
the accumulated scientific knowledge and experience, regulatory authorities tend to increasingly confide in the 
advanced biopharmaceutics tools. The regulatory recognition is reflected in the increased number of relevant 
submissions, as well as the recent scientific guidelines issued by the EMA and FDA [21,41,53-55].  
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SAŽETAK 
Integrisani biofarmaceutski pristup u razvoju i karakterizaciji lekova: opšti koncept i primena 
Sandra V. Cvijić, Svetlana R. Ibrić I Jelena V. Parojčić 
Univerzitet u Beogradu – Farmaceutski fakultet, Beograd, Srbija 
(Stručni rad) 
Značaj biofarmaceutskih razmatranja u razvoju i karakterizaciji lekova s ciljem 
uspostavljanja korelacije i mogućnosti predviđanja odnosa između in vitro podataka, 
odnosno karakteristika kvaliteta leka i njegovog in vivo ponašanja/kliničkog učinka, 
prepoznata je kako od strane farmaceutske industrije, tako i od strane odgovarajućih 
regulatornih tela. U radu je dat pregled savremenih biofarmaceutskih alata, uključujući 
prediktivno ispitivanje brzine rastvaranja lekovite supstance iz farmaceutskog oblika 
leka, Biofarmaceutski sistem klasifikacije, fiziološki zasnovano farmakokinetičko i 
biofarmaceutsko modelovanje i simulacije, in vitro-in vivo korelaciju i mogućnost 
izostavljanja in vivo studija bioekvivalencije (engl. biowaiver) iz aspekta opštih principa 
i mogućnosti primene u razvoju i karakterizaciji lekova. Predstavljena je i nedavno 
osmišljena inovativna strategija za razvoj leka usmerena ka pacijentu, uz primenu 
integrisanog sistemskog pristupa zasnovanog na osnovnim biofarmaceutskim 
konceptima, uvidu u kliničku situaciju i definisanim terapijskim ciljevima označena kao 
Plan aktivnosti za procenu biofarmaceutskog rizika (engl. Biopharmaceutics Risk 
Assessment Roadmap, BioRAM). Očekuje se da će daljem razvoju u ovoj oblasti najviše 
doprineti združene aktivnosti i razmena znanja i iskustava između farmaceutskih 
kompanija i regulatornih agencija sa zajedničkim ciljem da se ubrza razvoj efikasnih i 
bezbednih lekova dizajniranih u skladu sa potrebama i očekivanjima pacijenata. 
Ključne reči: izostavljanje in vivo stu-
dija; klinički učinak; ispitivanje brzine ras-
tvaranja; in vitro-in vivo korelacija; fiziolo-
ški zasnovani farmakokinetički/biofarma-
ceutski modeli 
